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and  survival.  RelA/p65  and  p50  are  the most  common NF‐κB  subunits  and  involved  in  the  classical NF‐κB
pathway. However, the prognostic and biological significance of RelA/p65 is equivocal in the field. In this study,
we assessed RelA/p65 nuclear expression by immunohistochemistry in 487  patients with de novo diffuse  large 















Diffuse large B-cell lymphoma (DLBCL), the most 
common form of aggressive non-Hodgkin lymphoma, 
accounts for nearly 40% of non-Hodgkin lymphomas 
[1]. Although most cases of DLBCL are curable with 
the standard immunochemotherapy regimen, rituximab 
plus cyclophosphamide, hydroxydaunomycin, vincris-
tine, and prednisone (R-CHOP), 30-40% of patients 
have drug-resistant disease or recurrence [2]. DLBCL is 
a highly heterogeneous disease. Based on gene 
expression profiling (GEP), DLBCL can be classified 
into two molecular subtypes: germinal center B-cell–
like (GCB) and activated B-cell–like (ABC) DLBCL 
[3]. The ABC subtype of DLBCL typically exhibits 
constitutive activation of the nuclear factor-kappaB 
(NF-κB) pathway [4, 5] and patients have inferior 
clinical outcomes compared with patients with GCB-
DLBCL [6, 7]. Recent studies have shown that NF-κB 
expression is not limited to ABC-DLBCL but also can 
occur in GCB-DLBCL [8-10]. 
 
The NF-κB/Rel family contains five transcription 
factors: RelA (p65), NF-κB1 (p50; p105), NF-κB2 
(p52; p100), RelB, and c-Rel. Only RelA/p65, RelB, 
and c-Rel had transactivation domains [11]. NF-κB 
activity is controlled by inhibitors of NF-κB (such as 
IκBα which inhibits p65/p50 dimers) that keep NF-κB 
inactive in the cytoplasm. Constitutive activation of NF-
κB in ABC-DLBCL is caused by chronic activation of 
B-cell-receptor (BCR) signaling and elevated IκB 
kinase (IKK) activities which phosphorylate IκBα. As a 
result, IκBα is degraded releasing homo- or hetero-
dimers of NF-κB to enter the nucleus where NF-κB 
activates gene transcription [4, 12-14]. In vivo the most 
abundant NF-κB dimers are p50/p65 heterodimers 
which are ubiquitously expressed in mammalian tissue 
[11, 15-17], consistent with the highest level of nuclear 
p50/p65 in DLBCL samples among all NF-κB subunits 
by our previous studies [10, 18]. Detection of p65/p50 
nuclear expression in tumor cells has been considered as 
a surrogate marker of NF-κB activation through the 












homodimers with distinct DNA-binding modes and 
functions [19-21].  
 
NF-κB activation suppresses apoptosis and promotes 
tumor cell survival and proliferation, leading to 
treatment resistance. Different NF-κB subunits had 
distinct and overlapping functions [22-24]. In addition, 
transcriptional and functional crosstalk between 
antiapoptotic NF-κB and proapoptotic p53 (an essential 
tumor suppressor) plays a critical role in determining 
the fate of tumor cells [25, 26]. The p65 subunit of NF-
κB and p53 counteract each other’s function in 
regulating cell proliferation, metabolism and apoptosis 
[25, 27-29]. p65 increases MDM2 levels, which 
decrease the stabilization of p53 and cell death induced 
by cytotoxic chemotherapy [25]. However, cooperation 
between p65 and p53 has been also reported [30-33], 
making interactions between p65/NF-κB and p53 much 
more complicated. Both p53 and p65 were unexpectedly 
found necessary for either p53 or NF-κB-directed gene 
transcription under replicational stress or atypical and 
classical stimuli for NF-κB. Induced p65 in stimulated 
cancer cells by pro-inflammatory tumor necrosis factor 
α (TNF-α) binds to p53 and the p65/p53 complex 
transcriptionally activates NF-κB target genes 
(survivin/BIRC5, BCL2, BCL-XL, and FASL) [32]. 
Moreover, p65 and p53 co-regulate induction of 
proinflammatory genes in monocytes and macrophages 
[33]. 
 
Despite the well-established role of NF-κB signaling in 
lymphoma pathogenesis and treatment resistance, 
conflicting results on the prognostic significance of NF-
κB and RelA/p65 expression (as a surrogate marker of 
NF-κB activation) in DLBCL have been reported by 
previous clinical studies [8, 9, 34-36]. To help clarify 
the prognostic effect of RelA/p65 nuclear expression, in 
this study we evaluated nuclear expression of RelA/p65 
by immunohistochemistry (IHC) in a large cohort of 
DLBCL treated with R-CHOP, and studied the prog-
nostic effects  and  gene  expression  profiles  associated 
B‐cell lymphoma (DLBCL), and studied the effects of molecular and pharmacological inhibition of NF‐κB on cell
viability.  We  found  RelA/p65  nuclear  expression,  without  associations  with  other  apparent  genetic  or
phenotypic  abnormalities,  had  unfavorable  prognostic  impact  in  patients  with  stage  I/II  DLBCL.  Gene
expressionprofiling analysis suggested immune dysregulation and antiapoptosis may be relevant for the poorer
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with p65 nuclear expression. Moreover, we inactivated 
individual NF-κB subunits in vitro and investigated 
their differential effects on proliferation and apoptosis 
of DLBCL cells which highlighted the important 




p65 hyperactivation has significant adverse 
impact in early-stage DLBCL 
 
p65 expression was evaluable in 487 DLBCL patients, 
including 287 men and 200 women. GCB/ABC ratio 
was close to 1 (243 GCB and 239 ABC). The median 
age of the patients in the study group was 63 years, and 
58% of the study cohort had elderly age (≥60). 
Immunohistochemical results showed that 58% of 
DLBCL samples had p65 nuclear expression indicative 
of p65 activation at various levels (Fig. 1A) with a 
mean level of 14%. p65 nuclear expression was not 
specific for ABC-DLBCL. In fact, the GCB-DLBCL 
group had a slightly higher mean level of p65 nuclear 
expression (16.1%) than the ABC-DLBC group (12.6%) 
(Fig. 1A). Table 1 showed the clinical and pathological 
features of the study cohort. 
 
Low levels (10-40%) of p65 nuclear expression did not 
have significant prognostic impact in DLBCL (Fig. 1B). 
However, high p65 nuclear expression (p65high, ≥50% 
tumor cells with p65 positive nuclei) correlated with 
significantly shorter PFS and OS durations in patients 
with stage I/II DLBCL and in patients with an 
International Prognostic Index score (IPI) ≤2 (Fig. 1B, 
Fig. 2A). In contrast, in patients with stage III/IV 
DLBCL or an IPI >2, p65 expression was not 
prognostic. p65high patients with stage I/II DLBCL had 
similar survival rates compared with p65high patients 
with stage III/IV DLBCL (Fig. 2B). 
 
When analyzed individually in GCB and ABC subtypes, 
in GCB-DLBCL only, the p65high group frequently had 
large (≥ 5cm) tumors (65% vs. 37%, P = 0.011) (Table 
1), and significantly decreased PFS (P = 0.04, Fig. 2C) 
and OS (P = 0.015) rates than other patients (p65low 
group, IHC <50%). However, the unfavorable 
prognostic effect  manifested in GCB-DLBCL was 
limited in stage I/II (Fig. 1C) and minimal in stage 
III/IV GCB-DLBCL (P = 0.95 for PFS and P = 0.60 for 
OS); also, in stage I/II ABC-DLBCL patients, p65high 
expression also significantly correlated with worse PFS 
(Fig. 1C).  
 
p65 nuclear expression correlates with p50 nuclear 
expression in DLBCL  
 
We found high p65 nuclear expression was significantly  
associated with p50+ and p50high nuclear expression in 
overall DLBCL, GCB-DLBCL, and ABC-DLBCL 
(Table 1), suggesting the predominance of p65/p50 
dimer activation via the canonical NF-κB pathway [9]. 
Significant association with c-Rel+ nuclear expression 
was also found in overall DLBCL and GCB-DLBCL 
(p50/c-Rel is another dimer activated via the canonical 
pathway [37, 38]). No significant association was 
observed between p65high and RelB+. p65high showed 
significant association with p52+ in overall DLBCL but 
not in either GCB or ABC subset.  
 
Nuclear expression of p50, p52, and c-Rel did not show 
further prognostic effects among the p65high patients. 
We did not observe associations of p65high with any 
other adverse biomarkers such as TP53 mutations, 
MYC/BCL2 translocation, and Myc/Bcl-2 over-
expression which may confound the prognostic effects 
[39-42]. In contrast, in the GCB but not the ABC 
subgroup, p65high compared with p65low patients less 
frequently had Bcl-2 overexpression (18% vs. 40%, P = 
0.036). 
 
p65 hyperactivation has significant adverse impact 
in patients with wild-type TP53 
 
Cases of DLBCL with wild-type TP53 (WT-TP53) had 
significantly lower levels of RELA mRNA (P = 0.018, 
Fig. 1D) and a trend toward lower nuclear p65 levels (P 
= 0.11) than those with mutated TP53 (MUT-TP53), 
suggesting that wild-type p53 suppressed RELA NF-κB 
expression. Conversely, p65 antagonized p53 function 
as suggested by survival analysis: in WT-TP53 DLBCL, 
patients with p65high expression correlated with 
significantly decreased PFS (P = 0.0076, Fig. 2C) and 
OS (P = 0.0082) rates than patients with p65low tumors, 
independent of GCB and ABC cell-of-origin. However, 
when subdivided cohorts by disease stages, we found 
the prognostic impact was only significant in patients 
with stage I/II disease (P < 0.0001 for PFS, P = 0.0004 
for OS). Also in MUT-TP53 patients with stage I/II 
DLBCL, positive p65 nuclear expression was associated 
with significant poorer survival; in contrast, opposite 
trends were observed in MUT-TP53 patients with stage 
III/IV DLBCL (Fig. 1E).  
 
Multivariate survival analysis 
 
Multivariate survival analysis (Cox regression) for high 
p65 nuclear expression with adjustments for clinical 
variables confirmed that p65high was an independent 
adverse prognostic factor in patients with GCB-DLBCL 
and in patients with WT-TP53 DLBCL, but not in the 
overall study group, the ABC-DLBCL subgroup, or the 
MUT-TP53 DLBCL subgroup (Table 2).  

















































































































Figure 1. Nuclear expression of p65 and  its effect on progression‐free  survival  (PFS)  in diffuse  large B‐cell  lymphoma


























































































































 DLBCL  GCB-DLBCL  ABC-DLBCL  WT-TP53  MUT-TP53  
 p65high p65low P  p65high p65low P p65high p65low P p65high p65low  P p65high p65low P 
Characteristics N (%) N (%)  N (%) N (%)  N (%) N (%)  N (%) N (%)  N (%) N (%)  
Patients 41 446  28 215  13 226  26 312  12 84  
Age (years)                
<60 21 (51) 
183 
(41) 0.21 16 (57) 
106 
(49) 0.44 5 (39) 74 (33) 0.67 
13 
(50) 124 (40) 0.31 7 (58) 30 (36) 0.13 
≥60 20 (49) 
263 
(59)  12 (43) 
109 
(51)  8 (61) 152 (67)  
13 
(50) 188 (60)  5 (42) 54 (64)  
Gender                
Female 8 (20) 192 (43) 0.003 6 (21) 95 (44) 0.022 2 (15) 95 (42) 0.057 6 (30) 130 (42) 0.063 2 (17) 38 (45) 0.06 
Male 33 (80) 
254 




(85) 131 (58)  
20 
(70) 182 (58)  10 (83) 46 (55)  
Stage                
I/II 19 (46) 
203 
(47) 0.90 15 (54) 
114 
(56) 0.84 4 (31) 86 (39) 0.54 
11 
(42) 141 (48) 0.60 6 (50) 39 (46) 0.82 
III/IV 22 (54) 
226 
(53)  13 (46) 91 (45)  9 (69) 133 (61)  
15 
(58) 155 (52)  6 (50) 45 (54)  
B-symptoms                
No 25 (61) 
272 
(64) 0.67 18 (64) 
141 
(70) 0.55 7 (54) 127 (59) 0.73 
16 
(61) 196 (66) 0.61 7 (58) 54 (68) 0.53 
Yes 16 (39) 
151 
(36)  10 (36) 61 (30)  6 (46) 89 (41)  
10 
(39) 99 (34)  5 (42) 26 (33)  
LDH levels                
Normal 14 (34) 
161 
(40) 0.51 8 (29) 86 (44) 0.12 6 (46) 74 (36) 0.44 
10 
(39) 121 (43) 0.65 3 (25) 28 (36) 0.46 
Elevated 27 (66) 
247 
(60)  20 (71) 
109 
(56)  7 (54) 134 (64)  
16 
(61) 160 (57)  9 (75) 50 (64)  
Extranodal sites (n)               
0–1 35 (85) 
327 




(92) 163 (74) 0.15 
21 
(81) 231 (79) 0.79 11 (92) 64 (78) 0.27 
≥2 6 (15) 98 (23)  5 (18) 41 (20)  1 (8) 56 (26)  5 (19) 63 (21)  1 (8) 18 (22)  
Performance status               
0–1 34 (87) 
329 




(92) 166 (80) 0.33 
22 
(85) 231 (85) 0.93 10 (91) 69 (90) 0.89 
≥2 5 (13) 66 (17)  4 (15) 25 (14)  1 (8) 41 (20)  4 (15) 40 (15)  1 (9) 8 (10)  
Size of largest tumor               
<5cm 14 (44) 
192 
(58) 0.11 8 (35) 97 (63) 0.011 6 (67) 93 (54) 0.47 8 (38) 146 (62) 0.035 5 (50) 33 (49) 0.96 
≥5cm 18 (56) 
137 
(42)  15 (65) 58 (37)  3 (33) 78 (46)  
13 
(62) 91 (38)  5 (50) 34 (51)  
IPI risk 
group                
0–2 29 (71) 
267 
(62) 0.25 21 (75) 
144 
(71) 0.82 8 (61) 118 (54) 0.78 
17 
(65) 189 (63) 1.0 10 (83) 47 (57) 0.12 
3-5 12 (29) 
162 
(38)  7 (25) 60 (29)  5 (39) 102 (46)  9 (35) 109 (37)  2 (17) 43 (35)  
Therapy response               
CR 29 (71) 
343 




(92) 172 (76) 0.18 
17 
(65) 257 (82) 0.034 9 (75) 49 (58) 0.27 
Non-CR 12 (29) 
103 
(23)  11 (39) 49 (23)  1 (8) 22 (24)  9 (35) 55 (18)  3 (25) 35 (42)  
Primary origin               
Extranodal 20 (49) 
149 
(34) 0.058 14 (50) 68 (32) 0.063 6 (46) 79 (36) 0.44 
14 
(54) 102 (33) 0.035 4 (33) 26 (32) 0.91 
Nodal  21 (51) 
289 
(66)  14 (50) 
143 
(68)  7 (54) 143 (64)  
12 
(46) 204 (67)  8 (67) 56 (68)  
 


















































































































origin                
GCB 28 (68) 215 (49) 0.022 - - - - - - 
18 
(69) 143 (46) 0.039 9 (75) 49 (58) 0.35 
ABC 13 (32) 226 (51)  - -  - -   8 (31) 165 (54)  3 (25) 35 (42)  
p50 nuclear expression               
<20% 15 (40) 278 (67) 0.002 12 (46) 
149 
(74) 0.005 3 (27) 129 (60) 0.05 9 (41) 188 (65) 0.037 6 (50) 57 (71) 0.18 
≥20% 22 (60) 138 (33)  14 (54) 52 (26)  8 (73) 85 (40)  
13 
(59) 102 (35)  6 (50) 23 (29)  
p52 nuclear expression               
– 21 (55) 300 (71) 0.043 14 (54) 
142 
(71) 0.11 7 (58) 157 (72) 0.33 
14 
(58) 208 (71) 0.25 5 (46) 59 (74) 0.078 
+ 17 (45) 120 (29)  12 (46) 58 (29)  5 (42) 61 (28)  
10 
(42) 86 (29)  6 (54) 21 (26)  
c-Rel nuclear 
expression               
– 17 (46) 297 (72) 0.002 11 (44) 
147 
(74) 0.004 6 (50) 150 (70) 0.20 9 (41) 207 (73) 0.003 7 (58) 55 (67) 0.53 
+ 20 (54) 117 (28)  14 (56) 52 (26)  6 (50) 64 (30)  
13 
(59) 78 (27)  5 (42) 27 (33)  
Bcl-2 expression               
<70% 27 (66) 229 (52) 0.10 23 (82) 
127 
(60) 0.036 4 (31) 99 (44) 0.40 
17 
(65) 164 (53) 0.31 7 (58) 40 (48) 0.55 








  Overall survival Progression-free survival
 HR 95% CI P HR 95% CI P
DLBCL (n = 497)   
IPI > 2 2.41 1.70–3.42 < 0.001 2.29 1.64–3.19 < 0.001
Female sex 1.03 0.72–1.49 0.86 0.99 0.70–1.41 0.98
Tumor size ≥ 5 1.28 0.91–1.81 0.16 1.23 0.89–1.71 0.21
B-symptoms 1.35 0.94–1.94 0.099 1.31 0.93–1.85 0.12
p65high 1.56 0.91–2.68 0.11 1.44 0.85–2.42 0.18
GCB-DLBCL  (n = 243)   
IPI > 2 2.47 1.40–4.38 0.002 2.39 1.39–4.09 0.002
Female sex 1.00 0.55–1.82 1.00 0.98 0.56–1.71 0.95
Tumor size ≥ 5 1.30 0.88–1.91 0.19 1.40 0.82–2.40 0.22
B-symptoms 1.44 0.80–2.58 0.22 1.34 0.77–2.33 0.31
p65high 2.30 1.14–4.62 0.02 2.01 1.06–3.82 0.034
WT-TP53 DLBCL  (n = 338)   
IPI > 2 2.54 1.66–3.88 < 0.001 2.33 1.57–3.46 < 0.001
Female sex 0.98 0.63–1.53 0.92 0.99 0.65–1.51 0.96
Tumor size ≥ 5 1.20 0.79–1.84 0.39 1.09 0.73–1.63 0.18
B-symptoms 1.59 1.04–2.43 0.034 1.57 1.05–2.33 0.028
p65high 1.91 1.04–3.52 0.037 1.94 1.08–3.48 0.026
Abbreviations: R‐CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; CI, 
confidence  interval;  IPI,  International Prognostic  Index; p65high, high  levels of nuclear p65; GCB, germinal center B‐cell–
like; ABC, activated B‐cell–like; WT‐TP53, wild‐type TP53. *Significant P values in bold. 
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GEP analysis suggests different signaling pathways 
activated in GCB- and ABC-DLBCL  
 
To gain insight into the molecular mechanisms 
underlying the prognostic effects of p65 hyperactivation 
in DLBCL, we compared gene expression profiles of 
p65high and p65low tumors. p65high patients showed GEP 
signatures compared with other DLBCL including p65− 
DLBCL patients (IHC <10%), stronger in GCB-















































In line with the unfavorable prognosis of patients with 
p65high DLBCL, GEP analysis found that JUN and 
PTPRD (involved in cell cycle progression) were 
upregulated (1.43-fold and 1.31-fold respectively) 
whereas pro-apoptotic NOXA/PMAIP1 and BTG3 which 
negatively regulates proliferation and cell cycle 
progression were downregulated (1.62-fold and 1.45-
fold, respectively) in p65high DLBCL compared with 
p65low DLBCL. RBMS1 which transactivates MYC was 
upregulated (1.48-fold) in p65high compared with p65low 
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BIRC6, MCM10 (involved in the initiation of eukaryotic 
genome replication), CARS (cysteinyl-tRNA synthetase) 
and PA2G4 (involved in growth regulation) were 
downregulated in p65high patients, and TENC1 (which 
inhibits AKT1 signaling) was upregulated in p65high 
DLBCL.  
 
When analyzed in GCB and ABC subtypes individually, 















































the GCB subset. RNF130 involved in apoptosis showed 
1.81-fold upregulation in p65high GCB-DLBCL patients. 
In contrast, in p65high ABC-DLBCL, antiapoptotic 
BIRC5 and BCL2L2 were significantly upregulated 
whereas pro-apoptotic NOXA/PMAIP1 was significantly 
downregulated (Fig. 3B-C), in addition to the 
proliferative signatures (such as upregulation of genes 
involved in replication, transcription, translation, and 



















































  p65high vs. p65low    
Functional 
categories 
In overall DLBCL 
(FDR <0.30)  
In GCB-DLBCL (FDR 
<0.05)  




TNFRSF1A ↑ FYN ↑ LCP2 ↑ 
PTPRD ↑ GTPBP2 ↑ PROCR 
↑ TENC1 ↑ ITPR3 ↑ TEK ↑ 
CACNA2D1 ↑ AGTRAP ↑ 
LPAR3 ↓ 
 MT1X ↑ MT1G ↑ SERPING1 ↑ PSEN1 ↑  
ARHGEF2 ↑ FGFBP1 ↑ 




  CD163 ↑ FCER1G ↑ CYBB ↑ GRN ↑ CD84 ↑ LILRB1 ↑  DEFB4 ↑ 





JUN ↑ MLLT10 ↑ GATAD2A 
↑ HOXD10 ↑ NFRKB ↑ 
ZWINT ↓ MCM10 ↓ HMGB1 ↓ 
PPP2CA ↓UHRF1 ↓ BTG3 ↓ 
ZNF254 ↓ CARS ↓ PA2G4 ↓ 
SERBP1 ↓ 
 RBMS1 ↑ ANKRD11 ↑ FAM89B ↑  ESRP1 ↑ DPPA4 ↑  
Apoptosis PMAIP1 ↓ BIRC6 ↓  RNF130 ↑   
Metabolism SULT1A1 ↑ SPTLC2 ↑ SLC25A16 ↑ SLC9A9 ↑  
GLUL ↑ SERINC1 ↑ CAT ↑ 





CPNE8 ↑ DNAJC5 ↑ RHD ↑ 
AGFG2 ↑  
SLC8A1 ↑ NPC2 ↑ VAMP5 






SH3D19 ↑ ITGA6 ↑ MYLK ↑ 
COL6A1 ↑ UTRN ↑ FMOD ↑  UTRN ↑   
CCDC151 ↑ KRT13 ↑ 
ANTXR2 ↑ COL17A1 ↑ 
Degradation, 




NCRNA00185 ↑ C19orf6 ↑ 
PLEKHO2 ↑ FAM124A ↑  
MT1P2 ↑ ZDHHC20 ↑ 
PLEKHO2 ↑  
FAM105B ↓ CG030 ↑ 
NCRNA00185 ↑ IQCG ↑  
Abbreviations:  p65high,  p65  immunohistochemistry  results:  ≥50%  nuclear  expression;  p65low,  p65  immunohistochemistry 
results:  <50%  nuclear  expression; GCB,  germinal  center  B‐cell–like;  ABC,  activated  B‐cell–like;  FDR,  false  discovery  rate. 
*Upregulated genes in bold. 

















































































































Figure 3. Gene expression profiling analysis.  (A) Heatmaps  for comparisons between DLBCL patients with p65high expression  (IHC
≥50%) and those without p65 nuclear expression (IHC <10%) in the overall and GCB‐DLBCL cohorts (FDR <0.15 and FDR <0.05, respectively).
(B) BIRC5/survivin and BCL2L2 were  significantly upregulated  in p65high ABC‐DLBCL.  (C) NOXA/PMAIP1 was  significantly downregulated  in
p65high ABC‐DLBCL. (D‐E) BTK and TNFRSF13B were significantly upregulated in the p65high group in ABC‐DLBCL but not in GCB‐DLBCL. (F‐
H) MAP3K14/NIK, MYD88, and TNFRSF13C were significantly upregulated in the p65high group in GCB‐DLBCL but not in ABC‐DLBCL.  
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GEP suggested that in GCB-DLBCL, instead of 
antiapoptotic mechanisms, dysregulations in immune 
responses and tumor microenvironment may be relevant 
for the poor prognosis associated with p65high. Such 
immune signatures included FCER1G (Fc fragment of 
IgE high affinity I receptor for gamma subunit), 2.21-
fold upregulation, CYBB (critical component of 
phagocytes generating superoxide), 1.77-fold 
upregulation, granulin gene GRN, 1.63-fold up-
regulation, LILRB1 (a MHC class I receptor resulting in 
immunosuppression), 1.49-fold upregulation, CD163 
(an antigen exclusively expressed in monocytes and 












































adhesion molecule involved in regulating receptor-
mediated signaling in immune cells), 1.55-fold up-
regulation. In the GEP comparison in overall DLBCL, a 
few immune-related genes were also found up- or 
down-regulated in p65high DLBCL compared with 
p65low DLBCL, including upregulation of LCP2 
(lymphocyte cytosolic protein 2, involved in T cell 
receptor signaling, 1.27-fold) and TEK (anti-
inflammatory, 1.21-fold), and downregulation of 
UHRF1 (an epigenetic regulator promoting proliferation 
of immunosuppressive Treg cell, 1.48-fold down-






















































































These data indicated that the antiapoptotic and pro-
proliferation function of p65 was primarily activated in 
ABC-DLBCL, whereas immune dysregulation might be 
more relevant for the significantly adverse impact of 
p65 hyperactivation in GCB-DLBCL. We further 
analyzed the expression of p65-activating upstream 
signals in GCB- and ABC-DLBCL. TNFRSF1A en-
coding a TNF-α receptor which can activate NF-κB by 
degrading inhibitory IkBα (canonical activation), was 
upregulated in the overall p65high group than in the 
overall p65low group (P = 0.0001). LPAR3 which 
encodes a receptor for lyso-phosphatidic acid/LPA was 
downregulated in p65high DLBCL. In the ABC-DLBCL 
subset only, PSMB1, which encodes a 20S core beta 
subunit of the proteasome B-type family, was 
upregulated in p65high compared with p65low patients 
(suggesting canonical activation of NF-kB). Bruton 
tyrosine kinase gene BTK which plays an important role 
in BCR signaling activation (canonical activation), and 





































receptor for APRIL and BAFF were significantly 
upregulated in p65high ABC-DLBCL but not in p65high 
GCB-DLBCL (Fig. 3D-E). In comparison, in GCB-
DLBCL but not in ABC-DLBCL, TNFRSF13C which 
encodes the receptor specific for BAFF (non-canonical 
activation), MYD88 which encodes an adapter protein 
essential for the Toll-like receptor (TLR) and 
interleukin-1 receptor signaling pathways, and 
MAP3K14/NIK which is involved in non-canonical 
activation of NF-κB were significantly upregulated in 
the p65high compared with p65low group (Fig. 3F-H).  
 
Targeting NF-κB in DLBCL cells 
 
Molecular inhibition of constitutive NF-κB activation 
in DLBCL cell lines 
 
First, we examined whether specific inhibition of NF-
κB was sufficient to block cell survival by over-




Functional categories  p65
high vs. p65− DLBCL (FDR 
<0.15) 
p65high GCB vs. p65− GCB (FDR 
<0.05) 
Signaling, ion channels IL10RA ↑ GPS2 /// D4S234E ↑ NOTCH3 ↑ VAV1 ↑ 
FAM26F ↑ MT1X ↑ MT1G ↑ 
MT2A ↑  MT1F ↑ CFLAR ↑ 
CLEC7A  ↑ 
Immune responses, inflammation GRN ↑ CD163 ↑ GRN ↑ FCER1G ↑ CD84 ↑ CYBB ↑ 
Cell cycle, DNA metabolism, 
transcription and translation 
regulation 
JUN ↑ PRDM1 ↑ GATAD2A ↑ 
TCF25 ↑ MLLT10 ↑ EP400 ↑ 
HOXD10 ↑ TAF1B ↓ ZNF254 ↓ 
RPL37A ↓ UHRF1 ↓ MCM10 ↓ 
BTG3 ↓ 
JUN ↑ GATAD2A ↑ RBMS1 ↑ 
Apoptosis TMBIM6 ↑ RNF130 ↑ BIRC6 ↓ RNF130 ↑ 
Metabolism, redox regulation 
SLC9A9 ↑ ATP6V0C ↑ 
SLC25A16 ↑ SAT1 ↑ SMPD1 ↑ 
C10orf58 ↑ HNMT ↑ GTPBP2 ↑
CPD ↑ GLUL ↑ SAT1 ↑  FTL ↑  
ANKRD11 ↑ SLC9A9 ↑ 
Transport, trafficking, protein 
folding, modification 
NPC2 ↑ WASH3P ↑ FTL ↑ GM2A 
↑ KDELR1 ↑ SLC39A7 ↑ CTSD ↑ 
CALU ↑ 
SLC8A1 ↑ GM2A ↑ DNAJC5 ↑ 
BCAP31 ↑ NPC2 ↑ 
Cell adhesion, cytoskeleton, 
collagen, extracellular matrix 
ITGB2 ↑ MYLK ↑ CD84 ↑ FMOD 
↑  
IQGAP1 ↑ UTRN ↑ 
Degradation CTSZ ↑ IDS ↑  
IDS  ↑ 
IncRNA genes, other function 
PLEKHO2 ↑ LOC100288142 /// 
NBPF1 /// NBPF10 ↑ CCHCR1 ↑ 
IGLJ3 ↑ DLEU2 /// DLEU2L ↓ 
NOL10 ↓ 
MT1P2 ↑ PLEKHO2 ↑ ZDHHC20 
↑ 
Abbreviations:  p65high,  high  p65  nuclear  expression  (immunohistochemistry  results:  ≥50%);  p65−,  negative  p65 
nuclear expression (immunohistochemistry results: <10%); FDR, false discovery rate. *Upregulated genes in bold. 
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(pCMV-IκBαM) in a representative DLBCL cell line, 
MS, that has been previously shown to have constitutive 
NF-κB activation [44]. IκBαM binds to NF-κB subunits 
but cannot be phosphorylated on the basis of alanine 
substitution for serines 32 and 36, acting as a dominant 
negative (DN) and thereby preventing the NF-κB 

















































transfection (70-80 efficiency and 75% viability) of a 
DLBCL-MS cell line with the DN-IκBαM leads to the 
induction of IκBα protein level while suppressing 
constitutive NF-κB activation (Fig. 5A). In addition, 
cells over-expressing the DN-IκBαM are prone to 
apoptosis as demonstrated by Annexin V binding assays  


















































Figure 5. Molecular  targeting of NF‐κB  in diffuse  large B‐cell  lymphoma  (DLBCL) cell  lines.  (A) DLBCL‐MS





Western  blot.  (D)  Indicated  DLBCL  cell  lines were  transfected with  the  validated  green  fluorescent  protein  (GFP)‐
plasmid–based shRNA for each of the NF‐κB subunits. After 16 hours, GFP–positive cells were sorted and assessed using
proliferation  assays.  Data  represent  two  independent  experiments  with  triplicate  samples.  Abbreviations:  GCB,
germinal center B‐cell–like; ABC, activated B‐cell–like, DN, dominant negative. 
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activation is required for the  survival  of  this  cell  line. 
To determine the functional significance of each NF-κB 
subunit on growth and survival regulation in DLBCL, 
we used specific validated shRNAs to selectively 
silence each NF-κB component individually in four 
representative DLBCL cell lines (two GCB-DLBCLs, 
two ABC-DLBCLs). These validated shRNAs inhibited 
endogenous NF-κB by more than 70% (Fig. 5C). 
Except for p52, downregulation of p65, c-Rel, and RelB 
protein expression with individual shRNAs inhibited 
DLBCL cell growth (thymidine incorporation assay), 
and inhibition of p65 was most effective (Fig. 5D), 
particularly in cell lines with mutated p53 (MS, LP and 
HB).  
 
Pharmacological targeting of constitutive NF-κB 
activation in DLBCL cells 
 
To evaluate the effects of pharmacological inhibition of 
NF-κB activation on transcription activities of NF-κB 



































ed the proteasome inhibitor bortezomib (BZ), and the 
small molecule NF-κB inhibitor BAY 11-7082 (BAY-
11) that selectively inhibits the phosphorylation and 
degradation of IκBα [45-47] in MS (GCB-DLBCL) 
cells.  
 
To ascertain whether BZ or BAY-11 has an effect on 
constitutive NF-κB activation in DLBCL cells, we 
performed EMSA with nuclear extracts purified from 
BZ- or BAY-11-treated GCB-DLBCL cell line (MS). 
After BZ or BAY-11 treatment, NF-κB DNA-binding 
activity (Fig. 6A) and the level of phosphorylated-IκBα 
(Fig. 6B) gradually declined in a dose-dependent 
manner in the MS DLBCL cell line. Confocal 
microscopy analysis also demonstrated that BZ or 
BAY-11 treatment inhibits the nuclear accumulation of 
p50 and p65 NF-κB subunits, leading to DNA 
fragmentation, indicative of cells undergoing apoptosis 
(Fig. 6C). Next, we evaluated the effects of BZ or 
BAY-11 on DLBCL cell viability using in vitro 






































(hours).  Nuclear  extracts  were  purified  and  subjected  to  EMSA  analyzed  for  NF‐κB  DNA  binding  activity;
cytoplasmic extracts were subjected to  immunobloting for pIκBa and actin. (C) DLBCL‐MS cells cultured  in the
presence of bortezomib  (BZ, 25 nM) or BAY‐11  (1 µM)  for 24 hours and  then analyzed  for p50  (red) and p65
(green) protein expression by confocal microscopy analysis.  Topro‐3 (blue) serves as a nuclear staining marker.
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lines (two ABC, two GCB). Both BZ and BAY-11 























































cell lines in a dose-dependent manner (Fig. 7A). BZ and 
























































(A)  Representative  ABC‐  and  GCB‐DLBCL  cell  lines  were  treated  with  bortezomib  (BZ)  or  BAY‐11  for  48  hours  and  cell
proliferation was measured  using  3H‐thymidine  incorporation  assays.  The  percentages  of  growth  inhibition  of  treated  cells
relative to untreated (control cells) were plotted. The data shown are the means and ranges of triplicate cultures from three
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analyzed the cell lysates from BZ-treated and BAY-11-
treated DLBCL-MS cells to a 20S proteasome 
proteolysis assay, and found proteasome activity was 
substantially inhibited (>50%) after 3 hours of BZ 
treatment, whereas BAY-11 treatment did not affect 
proteasome activity in a similar time points (Fig. 7B). 
To determine whether the cell growth inhibition effects 
of BZ and BAY-11 involve their activity in the cell 
cycle regulation, we analyzed the cell cycle profile. As 
shown in Fig. 7C, in a representative DLBCL cell line 
(MS), both BZ-and BAY-11-treated DLBCL cells 
accumulated in the G0/G1 phase of the cell cycle, while 
cells in G2M and S phases were decreased. In addition,  
BZ or BAY-11 treatments in MS DLBCL cell line 
resulting in cells undergoing apoptosis in a time-
dependent manner (Fig. 7D). To verify that these cells 
had actually undergone apoptosis, we measured the 
generation of caspase 3 activities. DLBCL cells treated 
with BZ or BAY-11 activated caspase 3 activity after 12 
hours of treatment, which can be block with a caspase 3 
inhibitor (DVED) but not with a caspase 1 inhibitor 
(VAD) (Fig. 7E). In addition, a known caspase 
substrate, poly-(ADP-ribose) polymerase (PARP), was 
cleaved after BZ or BAY-11 treatment (Fig. 7F). These 
experiments provide additional and interesting insights 
into the putative role of NF-κB in DLBCL cell 




In this study we studied the significance of RelA/p65 NF-
κB in DLBCL by two ways. In the first part of this study, 
we evaluated the prognostic significance of RelA/p65 
nuclear expression in a large cohort of de novo DLBCL 
treated with R-CHOP (n = 487). Although p65 nuclear 
expression may not be a strong prognostic marker in 
overall DLBCL, we found p65 hyperactivation (IHC 
≥50%) had significant adverse impact on survival of 
patients with stage I/II DLBCL independent of cell-of-
origin and TP53 mutation status, even though it was not 
associated with apparent genetic or phenotypic 
abnormalities, such as TP53 mutations, MYC/BCL2 
translocation, and Myc/Bcl-2 overexpression.  
 
The adverse prognostic significance of p65 
hyperactivation was also seen in the GCB-DLBCL 
subtype overall and in the subset with wild-type TP53, 
but not in the subsets with strong unfavorable factors 
including advanced stages, TP53 mutations, and ABC 
cell-of-origin. In addition, lower levels (10-40%) of p65 
nuclear expression did not have significant prognostic 
impact in DLBCL. This limited significance of p65 
expression in DLBCL may reflect different signaling 
transductions pathways activating p65, different p65 
NF-κB dimers, and complicated p65 functions 
influenced by other factors including p53 in different 
stimulatory signals. For example, NF-κB p65 activation 
induced by cytotoxic stimuli promotes apoptosis in 
mouse embryo fibroblasts, which contrasts with the 
prosurvival function of p65 induced by inflammatory 
cytokines [30]. In various cancer cell lines, p65 and p53 
formed p65/p53 complex and bound to DNA targets; 
the function of p65 and fate of tumor cells are 
significantly affected by p53 and stress levels [32]. 
Others have shown that there is transcriptional and 
functional crosstalk between NF-κB and p53. p53 can 
negatively regulate NF-κB activation by regulating 
IKK1 expression [29] and suppressing glycolysis [28]; 
NF-κB and p53 antagonize each other’s function in 
apoptosis, proliferation and tumor invasion that appears 
to depend on cellular context. Overall the results in this 
study suggested that p65 and wild-type p53 counter-
acted each other in DLBCL, and that the inhibition of 
p53 tumor suppressor function by p65 hyperactivation 
had a significant adverse impact on clinical outcomes. 
 
GEP suggested that BCR, TNF, TLR, and mitogen-
activated protein kinase signaling pathways were all 
implicated in p65 hyperactivation in DLBCL. These 
upstream pathways were activated preferably in ABC-
DLBCL or GCB-DLBCL, and correspondingly, 
resulting in different downstream pathways in ABC and 
GCB subtypes. In ABC-DLBCL, p65high GEP 
signatures were featured by proliferation and anti-
apoptosis, whereas in GCB-DLBCL in which subgroup 
p65 hyperactivation showed significant adverse 
prognostic impact, p65high expression was accompanied 
with upregulation of some pro-apoptosis genes as well 
as many immune genes. Upregulation of LILRB1 and 
CD163 in p65high patients suggested immune suppres-
sion and dysregulation, which may contribute to the 
associated poor prognosis.  
 
In the second part of this study, we tested whether NF-
κB p65 subunit in particular is a potential molecular 
target by the proteasome inhibitor bortezomib and the 
small molecule NF-κB inhibitor BAY-11 in vitro. 
Previous studies have shown that proteasome inhibitors 
have better antitumor efficacy in patients with ABC-
DLBCL than in patients with GCB-DLBCL, probably 
due to higher p65 expression in the ABC subtype [45, 
48, 52]. Consistently, our GEP analysis also found the 
proteasome gene PSMB1 was upregulated in ABC-
DLBCL. Our in vitro experiments found that these anti-
NF-κB agents can effectively inhibit p65 protein 
expression and DNA binding activity, leading to cell 
cycle arrest, decreased cell proliferation, and apoptosis 
induction in both GCB and ABC types of p65-
overexpressing DLBCL cell lines. Intriguingly, 
representative DLBCL cell lines with mutated p53 are 
more sensitive to p65 shRNA targeting approach as 
compared to a cell line with wild-type p53, opposite the 
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prognostic effects observed in the DLBCL study cohort. 
These findings may suggested that although p65 subunit 
only manifested prognostic significance in certain 
DLBCL subsets due to the complexity of NF-κB dimers 
and activating mechanisms, in vitro experiments 
nonetheless demonstrated that NF-κB overexpressing 
DLBCL cells were addictive to NF-κB and vulnerable 
for NF-κB inhibitors. This vulnerability of DLBCL cells 
was also apparent in the context of mutated p53; p65 may 
have an important role in the oncogenic activities of 
mutated p53 in DLBCL. Importantly,  in vitro p65 
subunit stood out as a critical factor in controlling cell 
growth and survival and showed the most sensitivity to 
molecular and pharmacological inhibition of NF-κB 
activation. Therefore, our current study in both patient 
samples and DLBCL cell lines provided additional 
insights into the putative roles of NF-κB p65 in immune 
regulation, DLBCL cell proliferation, and viability 
maintenance, and the utility of p65 as a biomarker to 
stratify DLBCL patients to receive alternative therapeutic 
regimens including agents targeting NF-κB [52]. 
However, these findings warrant further investigation and 
validation in more representative DLBCL cell lines as 
well as primary DLBCL cells.  
 
In summary, we provide clinical and experimental data 
that RelA/p65 NF-κB has prognostic and therapeutic 
value in DLBCL. High p65 nuclear expression is a 
significant adverse biomarker in patients with early-
stage (I/II) DLBCL. Pharmacological p65 inactivation 
effectively inhibited cell growth and survival in both 







The study cohort included 487 patients with de novo 
DLBCL treated with R-CHOP, as part of the 
International DLBCL R-CHOP Consortium Program. 
All patients were diagnosed as DLBCL between 2001 
and 2012 according to the World Health Organization 
classification criteria, and did not have a history of low-
grade B-cell lymphoma, primary mediastinal, 
cutaneous, central nervous system DLBCL, or human 
immunodeficiency virus infection. Informed consent 
was obtained from all patients. This study was 
conducted in accordance with the Helsinki Declaration 
and was approved by the Institutional Review Boards of 
all participating centers. GCB/ABC subtype 
classification by GEP or immuno-histochemistry 
algorithms [49], and TP53 mutation detection using p53 
AmpliChip [39] have been described previously. 
Overall survival (OS) was calculated from the date of 
diagnosis to the date of death from any cause or the date 
of last follow-up for censored patients. Progression-free 
survival (PFS) was calculated from the date of diagnosis 
to the date of disease progression, recurrence, or patient 
death from any cause. Survival analysis was performed 
using the Kaplan-Meier method and the log-rank 
(Mantel-Cox) test. The clinical features of DLBCL 
patients with high or low levels of p65 at the time of 
presentation were compared using the chi-square test. 
Univariate survival analysis was performed using the 
GraphPad Prism 6 (GraphPad Software, San Diego, 
CA). Multivariate survival analysis was performed 
using the Cox regression model and SPSS software 
(version 19.0; IBM Corporation, Armonk, NY). P 




Immunohistochemistry for p65 and other NF-κB 
subunits using specific antibodies (Abcam, Cambridge, 
MA) was performed on tissue microarrays of formalin-
fixed, paraffin-embedded lymphoma samples using 
methods described previously [10, 49]. The immuno-
histochemical stains were assessed in 10% increments 
by three pathologists blinded to the clinical outcomes. 
Disagreements about the percentage of positive cells 
were resolved by joint review at a multi-headed 
microscope.  
 
Gene expression profiling 
 
GEP was performed using the Affymetrix GeneChip 
Human Genome U133 Plus 2.0 array (Santa Clara, CA) 
and CEL files were deposited in the NCBI Gene 
Expression Omnibus repository (GSE#31312) [49]. 
GEP were available for 444 DLBCL patients of this 
study cohort with high or low levels of p65 nuclear 
expression. The P values for differential expression 
obtained via multiple t-tests were corrected for false 
discovery rates using the beta-uniform mixture method.  
 
In vitro studies 
 
Cell lines 
 Human DLBCL cell lines MS (mutated TP53) and DB 
(wild-type for p53) (GCB subtype), as well as LP 
(mutated TP53) and HB (mutated TP53) (ABC subtype) 
were previously characterized and described [44, 50]. 
The DLBCL cells were cultured in Roswell Park Memo-
rial Institute medium (Life Technologies, Carlsbad, CA) 
containing 15% fetal calf serum and 1% penicillin/ 
streptomycin (HyClone Laboratories, Logan, UT).   
 
Antibodies and small hairpin RNA plasmids 
The following primary antibodies were used: p50, p65, 
c-Rel and p52 (Millipore, Billerica, MA), and RelB 
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(Santa Cruz Biotechnology, Santa Cruz, CA). The 
SureSilencing small hairpin RNA (shRNA) green 
fluorescent protein (GFP)–based plasmids for the NF-
κB subunits p52, p65, c-Rel, and RelB were purchased 
from SuperArray Biosciences (Frederick, MD). pCMV-
IκBαM and control vectors were purchased from 
Clontech Laboratories (Mountain View, CA).  
 
Transfection 
Transfection experiments in DLBCL cells with 
validated green fluorescent protein (GFP)-shRNAs were 
performed in vitro in representative transfectable 
DLBCL cells, using the Neon transfection system from 
Invitrogen (Life Technologies Corporation, Grand 
Island, NY) as described previously [44], and were 
repeated at least twice to verify reproducible 
experimental results. Twenty-four hours after 
transfection, GFP+ cells were sorted by a fluorescence-
activated cell sorter (FACS) flow cytometer and plated. 
Cell proliferation was measured 96 hours after sorting 
by thymidine incorporation assays, while some cells 
were lysed for Western blot analysis for NF-κB subunit 
inhibition. A set of four shRNA plasmids for each NF-
κB subunit was tested and the optimal (>75%) gene 
knock-down shRNA plasmid was selected.   
 
Therapeutic NF-κB inhibition experiment 
DLBCL cells were treated with increasing doses of 
bortezomib (0–50 nM), or organic compounds BAY 11-
7082/BAY-11 (1µM) for 6-48 hours and subjected to 
cell proliferation assays, electromobility gel shift assay 
(EMSA), immunofluorescence, apoptosis detection 
assay, and cell cycle analysis according to the 
manufacturer's instructions or procedures as previously 
described [51]. Data are representative of three 
independent experiments.  
 
Thymidine incorporation assays 
In vitro thymidine incorporation proliferation assays 
were performed as described previously 1. Briefly, cells 
were plated (in triplicate) at 4.0 × 104 cells/well in 200 
μl of RPMI 1640 with 10% FCS and the indicated 
reagents in a 96-well plate and incubated in 5% CO2 at 
37°C. After 72 h, each well was pulsed with 0.5 μCi/10 
μl of [3H]thymidine (Amersham, Arlington Heights, IL) 
for 16 h. Cells were harvested and the radioactivity was 
measured. 
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